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Background:  Although  current  guidelines  recommended  surveillance  of  hepatocellular  carcinoma,  prog-
nosis  in patients  undergoing  enhanced  follow-up  has  yet to be  evaluated.
Aims:  Examine  outcomes  of hepatocellular  carcinoma  diagnosed  during  enhanced  follow-up.
Methods:  During  2010–2012,  194  patients  underwent  ultrasonography  surveillance  were  diagnosed  with
hepatocellular  carcinoma  and  divided  into:  (A) immediate  diagnosis  (N = 105, 54.1%)  after  positive ultra-
sonography,  (B)  enhanced  follow-up:  (N  = 38,  19.6%)  for initial  negative  recall  procedures,  (C)  late  call
back:  (N = 28,  14.4%)  recall  procedures  were  deferred  after  positive  ultrasonography,  and  (D)  beyond
ultrasonography:  (N = 23,  11.9%)  surveillance  ultrasonography  had  been  negative.
Results:  Median  time  from  positive  ultrasonography  to conﬁrmation  of  hepatocellular  carcinoma  were  9.5
months  (2–67)  in  the Group  B and  6.5 months  (3–44)  in  the  Group  C.  Stage  distribution  and 3-year  survival
rates  were  similar  amongst  all Groups.  Surveillance  intervals  longer  than  6 months  were  associated
with  the  non-curative  stage  (3.7%  vs.  12.5%, p = 0.04).  Nine  (4.6%)  patients  underwent  surveillance  were
diagnosed  as  Barcelona-Clinic  Liver  Cancer  stage  C.
Conclusion:  Enhanced  follow-up  by  current  guidelines  is  appropriate  that  treatment  can  be  deferred  until
a deﬁnite  diagnosis.  Despite  optimal  surveillance  interval  and  recall  policies,  few  non-curative  stage
diagnoses  seemed  inevitable  under  current  standard  of care.
©  2016  The  Authors.  Published  by  Elsevier  Ltd on  behalf  of  Editrice  Gastroenterologica  Italiana  S.r.l.
This  is an open  access  article  under  the  CC BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).. Introduction
Regular ultrasonography surveillance in patients with liver cir-
hosis or chronic viral hepatitis has improved the outcome of
epatocellular carcinoma (HCC) [1] owing to early diagnosis and
ppropriate curative treatment [2,3]. Current international guide-
ines advocate recall procedures, including: dynamic computer
omography (CT), magnetic resonance image (MRI), or biopsy in
ny suspicious liver nodule ≥1 cm for deﬁnite diagnosis [4–6];
ased on previous observation that nodules <1 cm were unlikely
o be HCC [7]. In addition, when two consecutive recall proce-
ures have been negative, the “enhanced follow-up” or similar
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emorial Hospital, 123 Ta Pei Road, Niao-Sung 833, Kaohsiung, Taiwan.
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ttp://dx.doi.org/10.1016/j.dld.2016.02.018
590-8658/© 2016 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroente
http://creativecommons.org/licenses/by-nc-nd/4.0/).strategies, by close ultrasonography follow-up and repeated
workup, are recommended by the American Association for the
Study of Liver Diseases as well as other guidelines [4–6]. How-
ever, in real world practice, not all patients receive immediate CT
or MRI  whenever a seemingly benign 1–2 cm nodule is detected;
in addition, some suspicious nodules during enhanced follow-
up are ultimately proved to be HCC after months or even years;
yet whether this represents a diagnostic delay was not known.
On the contrary, regular ultrasonography might well fail to show
tumors when a dynamic CT or MRI  conﬁrmed their presence
due to coarse liver parenchyma. These situations are not uncom-
mon, however, it is not known whether they are associated with
different outcomes or patient characteristics compared to other
patients whose HCC were immediately conﬁrmed by recall pro-
cedures after a positive surveillance ultrasonography. In this study,
we aimed to examine if different patterns of diagnosis affected
the outcome of patients receiving ultrasonography surveillance for
HCC.
rologica Italiana S.r.l. This is an open access article under the CC BY-NC-ND license
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. Material and methods
.1. Patient selection and deﬁnition of surveillance
ltrasonography
This is a single center, retrospective cohort study. From 2010
hrough 2012, a total of 194 patients with Child-Pugh class A or B
iver function status who’s HCC were detected during ultrasono-
raphy surveillance (the surveillance Group) in the tertiary referral
enter. In the same period, another 1098 patients who also had
hild-Pugh A or B status and HCC registration without regular
urveillance in the hospital, either by active referral from other
acilities or having symptomatic disease upon presentation, were
erved as the non-surveillance Group.
All the patients in the surveillance Group had to receive more
han one liver ultrasonography, performed by a hepatologist, one
ho is considered an expert in the diagnosis and treatment of
CC, within the preceding year before deﬁnite diagnosis was made.
ynamic images or liver biopsy might be arranged upon detection
f suspicious nodule(s) or as clinically indicated, and all the diag-
ostic images were reviewed by two hepatologists (YJH and LSN). In
aiwan, the common practice regarding ultrasonography surveil-
ance intervals were every 3–6 month in cirrhotic patients and
–12 month in other chronic liver disease patients. Accordingly,
n this study, the intervals were established by the referring physi-
ians (3 [ranged 1–4] month in 135 [69.6%], 6 [ranged 5–8] month
n 49 [25.2%], and 12 [ranged 9–12] month in 10 [5.2%] patients,
espectively).
The “positive ultrasonography” must fulﬁll the following crite-
ia: (1) any new nodules more than 1 cm were detected, (2) the
ocation and characteristics were consistent with the HCC biop-
ied or noted in the ﬁnal conﬁrmation image under critical review;
nd the duration from ﬁrst positive ultrasonography to ﬁnal con-
rmation of a tumor was documented. According to the patterns
f diagnosis, the surveillance Group was subdivided into four: (A)
mmediate diagnosis Group (n = 105, 54.1%): the diagnosis of HCC
as made by an immediate recall procedure after suspicious ultra-onography, (B) Enhanced follow-up Group (n = 38, 19.6%): the
nitial recall procedures were negative or indecisive, and the diag-
osis was made later through repeated workup during follow-up
Fig. 1), (C) Late call back Group (n = 28, 14.4%): ultrasonography
ig. 1. (a) This patient had a new 1.7 cm liver nodule found at segment 2 by ultrasonogr
nd  2011/06 failed to show any enhancing nodule. While stationary nodule size had been
white  arrow) was demonstrated by follow-up CT after 22 months. (b) Another patient h
typically enhancing pattern (white arrow). Serial aspiration biopsy had also been negati
ound  in 2009/12 ultrasonography. Repeat biopsy suggested poorly differentiate carcinom
eft  portal vein thrombosis (asterisk). Disease 48 (2016) 661–666
had revealed new ≥1 cm nodule(s) but the recall procedures were
performed at least three months later, (D) Beyond ultrasonogra-
phy Group (n = 23, 11.9%): the diagnosis of HCC were made purely
by dynamic CT or MRI  surveillance or any recall procedure trig-
gered by elevation of alpha-fetoprotein (AFP), and if the tumor
had never been detected by prior ultrasonography despite regu-
lar surveillance (Fig. 2). In Group C, the indications to receive recall
procedures altered the ultrasonography pattern of the suspicious
nodule (n = 20, 74.1%) and progressive AFP elevation (n = 7, 25.9%);
whereas in Group D, regular annual exam for cirrhotic patients with
overt coarse parenchyma [8] (n = 7, 30.3%) and elevated AFP (n = 16,
66.7%) accounted for these cases.
2.2. Diagnosis and staging of HCC
In this study, the diagnostic criteria adhered to current inter-
national guidelines [4–6] that either a typical dynamic image
or histologic proof was  required. For the purpose of this study,
Barcelona-Clinic Liver Cancer (BCLC) staging system [9] was used
in all the patient Groups. The BCLC stage 0 and A are referred as
“curative stage”, as curative treatments are mostly recommended
in this Group of patients; on the other hand, the BCLC stage B and
C were referred to as being in a non-curative stage.
2.3. Analysis of AFP level at and before diagnosis
Measurement of AFP was via enzyme-linked immunosorbent
assay (Architect reagent kit, Abbott). For the analysis of AFP, we
used AFP level at the time of earliest “positive ultrasonography” in
Group A–C, to investigate the associations between patterns of AFP
elevation and ultrasonography positivity; and AFP at the time upon
deﬁnite diagnosis of HCC in Group D since the ultrasonography had
been negative. Once a patient had been found to have an abnormally
high AFP level (above 20 ng/ml), we  traced his AFP level retrospec-
tively to check when their AFP began to rise. To classify the pattern
of AFP elevation, “abrupt elevation” was  deﬁned if one had high
AFP at diagnosis but the last value within 6 months was normal;
whereas “insidious elevation” referred to the AFP having been high
before diagnosis and the time from initial rise to diagnosis were
recorded.
aphy surveillance in 2009/12, however computerized tomography (CT) in 2010/02
 noted by subsequent ultrasonography; an early enhancing and wash-out pattern
ad a new 1.7 cm liver nodule found in 2007/09, and CT at the same time showed
ve. However, rapid tumor progression with suspicious portal vein thrombosis was
a and CT scan in 2010/03 conﬁrmed 5 cm tumor with early contrast washout and
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1325 P’t registered during 2010-2012 
in KCGMH HCC database
Immediate diagnosis
(N = 105, 54.1%)
Enhanced follow-up
 (N = 38, 19.6%) 
Late call back 
(N = 28, 14.4%) 
1098 without regular 
surveillance
33 excluded due to 
incomplete record or 
previous treatment
Surveillance group (194 patients) 
Beyond US 
(N = 23, 11.9%) 
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p = 0.04). The patterns of AFP elevation in both Groups, whether
abrupt or insidious, along with other baseline characteristics, were
similar (Table 2).Fig. 2. Patient classiﬁcation acc
.4. Statistical analysis
For this study SPSS version 22 was used to perform all tests
SPSS Inc., Chicago, IL). Statistical signiﬁcance was  determined for
hen the p value is less than 0.05. Continuous data are expressed
s means ± standard deviations or medians and ranges or in case of
ormal or non-normal distribution, respectively. We  used analysis
f variance to compare continuous data, and chi-square analysis or
he Fisher exact test to compare categorical variables. The Pearson
roduct moment was used to study correlations between contin-
ous variables. Survival analysis of the cumulative survival rate
rom diagnosis to March 2015 was performed via the Kaplan–Meier
urve with log-rank test. In the surveillance Group, the BCLC stage
erved as the primary end point and the three-year cumulative
urvival rates were the secondary end point.
.5. Ethics
We  established and managed the database while conforming
o current Taiwanese legislation on privacy and clinical study. The
ocal institutional review board in Chang Gung Memorial Hospital
pproved the study, and informed consent was not required in the
etrospective cohort study, as the local Institutional Review Board
ad permitted this.
. Results
.1. Stage distribution, characteristics and survival among
urveillance Groups
While marked stage migration was noted between surveil-
ance and non-surveillance Groups (83.1% vs. 36.6% within curative
tage at diagnosis, p < 0.001), the baseline characteristics, includ-
ng age, gender, etiology of hepatitis, prevalence of liver cirrhosis,
hild-Pugh score, BCLC stages, tumor number and size, or ultra-
onography surveillance intervals among Group A–D were not
ifferent. However, in the Group D (Beyond ultrasonography), the
roportion of abnormal high AFP, either using a cut-off value of
0 ng/ml (p < 0.001) or 200 ng/ml (p = 0.010), was  higher among
atients in Group C; whereas the biopsy-proven tumors was also
ess in this Group (p = 0.025, Table 1).
Although different in clinical course, the median time from the
rst positive ultrasonography to deﬁnite diagnosis was 9.5 months
2–67) in Group B and 6.5 months (3–44) in Group C, respectively. Of
ote, in Group B, 13 patients (34.2%) had >50% increase in tumor size
ound by ultrasonography before diagnosis, 7 patients (18.4%) had
rogression in size or enhance pattern by repeat dynamic images
espite stationary in ultrasonography exam; and the others were to inclusion/exclusion criteria.
conﬁrmed by serial recall procedures after the ﬁrst positive ultra-
sonography. The overall three-year survival rates were 75.0% in
Group A, 75.5% in Group B, 82.5% in Group C and 64.4% in Group
D, respectively, p = 0.882, Fig. 3.
The patterns of AFP elevation were analyzed and upon conﬁr-
mation of diagnosis, 68 (35.1%) patients had an AFP level higher
than 20 ng/ml. Among those with high AFP, 17 (25.0%) patients had
abrupt elevation, and 51 patients (75.0%) had insidious elevation
of AFP, with a median time of 7 (2–123) months; furthermore, in
patients having insidious elevation of AFP, ultrasonography exam
detected the suspicious nodule in 32 patients (62.7%) while other
19 patients (37.3%) remained negative in at the beginning of rising
AFP.
3.2. Early vs. non-early stage diagnosis of HCC in surveillance
Groups
We re-classiﬁed patients in the surveillance Group accord-
ing to whether they were in the curative stages, as 162 (83.5%)
were diagnosed at a curative stage and 32 (16.5%) were at a
non-curative stage. Comparison of baseline characteristics in both
Groups revealed patients in curative stage Group were more likely
to be diagnosed via biopsy (n/N = 25.3% vs. 9.4%, p = 0.049), in
addition, signiﬁcantly more patients in the non-curative stage
Group had twelve-month surveillance interval (n/N = 12.5% vs. 3.7%,Fig. 3. Kaplan–Meier survival curves of the surveillance subgroups.
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Table 1
Baseline characteristics in surveillance subgroups.
Immediate diagnosis (A)
(N = 105, 54.1%)
Enhanced follow-up (B)
(N = 38, 19.6%)
Late call back (C)
(N = 28, 14.4%)
Beyond US (D)
(N = 23, 11.9%)
pa
Age (median) 61 (32–82) 62 (39–87) 62 (41–78) 58 (42–82) 0.357
Gender ratio (male to female) 71:34 24:14 21:7 15:8 0.777
AFP
>20  ng/ml 36 (34.3%) 7 (18.4%) 7 (25.0%) 18 (78.3%) <0.001d
>200 ng/ml 13 (12.3%) 1 (2.6%) 2 (7.4%) 7 (30.4%) 0.010d
Maximal tumor size (cm) 2.75 ± 1.45 2.39 ± 1.02 2.44 ± 1.71 1.93 ± 0.07 0.051
Tumor numbers 0.123
Single tumor 76 (72.4%) 32 (84.2%) 15 (53.6%) 15 (65.2%)
Two  tumors 18 (17.1%) 5 (13.2%) 6 (21.4%) 5 (21.7%)
Three tumors 6 (5.7%) 1 (2.6%) 3 (10.7%) 0
>3  tumors 5 (4.8%) 0 4 (14.3%) 3 (13.0%)
Etiologyb 0.227
Hepatitis B 47 (44.8%) 17 (44.7%) 12 (42.9%) 14 (60.9%)
Hepatitis C 46 (43.8%) 17 (44.7%) 10 (35.7%) 8 (34.8%)
Hepatitis B+C 5 (4.8%) 0 0 0
Others  7 (6.7%) 4 (10.5%) 6 (21.4%) 1 (4.3%)
Chronic viral hepatitis 98 (93.3%) 34 (89.5%) 22 (78.6%) 22 (95.7%) 0.090
Pathologic diagnosis 28 (26.7%) 12 (31.6%) 3 (10.7%) 1 (4.3%) 0.025d
Image diagnosis 77 (72.3%)
(CT = 71/MRI = 6)
26 (68.4%)
(CT = 19/MRI = 7)
25 (89.3%)
(CT = 21/MRI = 4)
22 (95.7%)
(CT = 20/MRI = 2)
0.016d
Cirrhosis 99 (94.3%) 34 (89.5%) 25 (89.3%) 22 (95.7%) 0.622
Child-Pugh A 79 (79.8%)c 27 (79.4%)c 17 (68.0%)c 17 (73.3%)c 0.643
Child-Pugh B 20 (20.2%)c 7 (20.6%)c 8 (32.0%)c 5 (22.7%)c
Liver US interval 0.569
3 m 69 (65.7%) 29 (76.3%) 20 (71.4%) 17 (73.9%)
6  m 31 (29.5%) 6 (15.8%) 6 (21.4%) 6 (26.1%)
12  m 5 (4.8%) 3 (7.9%) 2 (7.2%) 0
US: ultrasonography.
a Based on chi-square test.
r non
3
A
p
l
T
B
s
nb The others included alcoholic hepatitis, non-alcoholic fatty liver disease or othe
c Proportions among the cirrhotic patients in each group.
d p < 0.05.
.3. Qualitative analysis of BCLC stage C patients
The characteristics, diagnostic modalities and patterns of
FP elevation listed in Table 3 were similar to that of other
atients with different stages. The Case 1 and Case 9 had
onger interval from positive ultrasonography to recall procedures
able 2
aseline characteristics comparison in patients with curative stage and non-curative
tage of hepatocellular carcinoma.
Curative stage
(0 and A)
(N = 162, 83.5%)
Non-curative
stage (B and C)
(N = 32, 16.5%)
pa
Age (median) 61.5 (32–87) 62.0 (42–82) 0.788
Gender ratio (male to female) 108:54 23:9 0.565
Median AFP (ng/ml) 11.5 (2.1–1499) 13.5 (2.0–3250) 0.806
AFP  > 20 ng/ml 58 (35.8%) 10 (31.3%) 0.622
Abrupt AFP elevation (%) 16/58 (27.6%) 1/10 (10.0%) 0.236
Hepatitisb 0.499
B  77 (47.5%) 13 (40.6%)
C 67 (41.4%) 14 (43.8%)
B+C 5 (3.0%) 0
Non-B or C 13 (8.0%) 5 (15.7%)
Pathologic diagnosis 41 (25.3%) 3 (9.4%) 0.049c
Cirrhosis 150 (92.6%) 31 (93.8%) 0.817
Child-Pugh A 120 21 0.104
Child-Pugh B 30 10
Interval 0.117
3  m 115 20
6  m 41 8
12 m 6 4
3  or 6 m 156 (96.3%) 28 (87.5%) 0.040c
12 m 6 (3.7%) 4 (12.5%)
a Based on chi-square test.
b The others included alcoholic hepatitis, non-alcoholic fatty liver disease or other
on-viral hepatitis related cirrhosis.
c p < 0.05.-viral hepatitis related cirrhosis.
(7 and 4 months, respectively); of note, in the latter, ultrasonogra-
phy had revealed a suspicious portal vein thrombosis 15 months
(with negative CT ﬁndings at that time) before the positive nodule
was seen. Case 2 was initially found with a 1.3 cm hypoechoic nod-
ule with indecisive CT and biopsy results. Annual CT scans showed
stationary tumor status over the following two  years; however,
owing to the progressive increase of the AFP level, an additional
dynamic CT conﬁrmed the diagnosis of HCC with portal vein throm-
bosis. Case 8 had abrupt elevation of AFP during surveillance, CT
showed atypically enhanced tumor whereas ultrasonography was
unable to detect it for biopsy; four months later, a repeated CT
conﬁrmed typical HCC with left portal vein thrombosis. The other
cases were soon conﬁrmed with recall procedures after positive
ultrasonography.
4. Discussion
In this study, our surveillance efﬁcacy were comparable to that
of lately large European cohort studies [10,11] and a Japanese sin-
gle center study [12]; in which the ultrasonography detection rate
of early HCC ranged from 70 to 90%; as well as remarkable stage
migration corresponding to the a recent systemic review on HCC
surveillance [13].
Furthermore, patients under ultrasonography surveillance were
further divided into four Groups based on different clinical and
ultrasonographic patterns and each represented a unique scenario
in the real world practice. The immediate diagnosis Group was the
prototype of HCC detected by regular surveillance; whereas the
enhanced follow-up Group may be either attributed to the limita-
tions of recall procedures, de-novo tumor growth in abnormal liver
parenchyma, or progressive dysplastic changes. It was extremely
important to determine which accounted for the most, since treat-
ment of dysplastic nodules had not conferred a survival beneﬁt [14].
If failed recall policies were the main cause, the prognosis would
J.-H. Yeh et al. / Digestive and Liver Disease 48 (2016) 661–666 665
Table  3
Baseline characteristics in patients with BCLC stage C (advanced) HCC.a
Case No. Gender Age Etiology of
hepatitis
Child
class
Positive
US
Recall
procedure
Surveillance
interval (month)
Groupb
(month to dx)
AFP at dx
(ng/ml)
Last AFP
(months ago)
No. 1 Male 51 Alcohol B Yes CT 3 C (7) 3.2 4.1 (3)
No.  2 Male 78 B A Yes CT 3 B (31) 108.0 19.0 (4)
No.  3 Female 66 C A Yes CT 3 A 5.6 6.2 (3)
No.  4 Male 62 C A Yes CT 3 A 2996.9 6.1 (8)c
No. 5 Male 71 C B Yes CT 6 A 1.7 5.8 (3)
No.  6 Male 63 B A Yes CT 3 A 1.9 1.6 (3)
No.  7 Male 61 B A Yes FNA 3 A 424.6 19.0 (4)c
No. 8 Male 55 B A No CT 3 D 1654.2 6.1 (7)c
No. 9 Female 69 B B Yes CT 3 C (4) 8.2 7.6 (5)
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aa BCLC: Barcelona-Clinic Liver Cancer; HCC: hepatocellular carcinoma.
b Group A: immediate diagnosis, B: enhanced follow-up, C: late call back, and D: 
c Abrupt and progressive elevation during the period; the interval values were no
ave probably been worse due to a diagnostic delay; on the con-
rary, given all tumors shown in conﬁrmatory study had to be linked
o initial positive ultrasonography in the Group and the median 9.5-
onth follow-up time to deﬁnite diagnosis, progressive dysplasia
ay  play an major role; although additional data was necessary to
onﬁrm the hypothesis. Take these ﬁndings together, the current
ecommendations on enhanced follow-up were appropriate and
ggressive treatment could be reserved only after deﬁnite diagnosis
as made.
On the other hand, the late call back Group stood for a spe-
ial population in that most of them had had 1–2 cm nodules
ith benign appearance judged by ultrasonography evaluation by
xpert hepatologists; therefore, in contrast to current guidelines,
he recall procedures were deferred with close ultrasonography
ollow-up until changes in AFP or size. Surprisingly, their progno-
is was not worse than other patients despite a median 6.5-month
eriod from ultrasonography to recall procedures. This might be
xplained by the situation in which many benign tumors includ-
ng hemangioma or regeneration/dysplastic nodules would share
he ultrasonographic features of early HCC [15]; in this case, the
ajority of recall procedures would be negative despite some early
alignancy were unable to excluded solely by ultrasonography.
esides, this Group might contain few patients who did not receive
 timely conﬁrmation study that might have been done earlier. We
ave to emphasize that while our ﬁndings suggested close ultra-
onography follow-up instead of obligatory recall procedures in
arefully selected cases with 1–2 cm liver nodules might be rea-
onable, it was far from sufﬁcient to change the guidelines, and
urther studies are necessary.
Despite lack of statistical signiﬁcance, the 3-year survival in the
eyond ultrasonography Group were lower than the others which
ight indicate a diagnostic challenge. In fact, up to two  thirds of
he patients in this Group received dynamic images only after rising
FP levels; while the role of AFP in surveillance had been controver-
ial, it served as a trigger to a few cases in our study. On the other
and, the annual CT or MRI  accounted for one third of diagnoses
hough they are seldom advocated outside Japan owing to higher
ost. Furthermore, the most up-to-date guideline of the Japanese
ociety of Hepatology recommended Primovist MRI  every 6–12
onths in viral hepatitis related cirrhosis, instead of conventional
ynamic images for better accuracy [16] and the recommendation
as recently adapted by some authors from the Italian Liver Cancer
roup [17].
Our work demonstrated that longer surveillance interval was
egatively associated with diagnosis of early HCC, consistent with
everal studies [3,18,19]; however, it could only account for 12%
f the cases at non-curative stages. Another recently study by
he Italian Liver Cancer group pointed out that with semi-annular
S surveillance, nearly half non-curative stage diagnosis may  be
ttributed to high AFP level (>1000 ng/ml), inﬁltrating tumor, ord US.
d in the table.
other features shared by BCLC stage C like vascular invasion or
tumor metastasis [20]. Therefore, in our study, we focused on the
possible predictive factors of the stage C disease since the limited
treatment options and poor prognosis always made both the physi-
cian and examinee frustrated. Although Lee et al. reported serum
AFP level over time might help increase screening efﬁcacy [21];
we failed to ﬁnd any relevance between patterns of AFP eleva-
tion and stage C disease. In addition, case-based analysis for BCLC
stage C patients in our patient Group found only two cases belong-
ing to Group C at best might be considered preventable. In other
words, it might indicate that the efﬁcacy of HCC surveillance was
still imperfect under the current standard of care should a few
inevitably fall into advanced stages. Despite that fact, a comprehen-
sive surveillance program, including well-trained personnel, high
quality equipment and proper surveillance intervals are essential
to get the best results.
Our study had several limitations: ﬁrst of all, it is a retrospective
study in a single tertiary medical center, and therefore the propor-
tions of cirrhosis were somewhat higher, with a few patients who
did not receive at least a biannual ultrasonography exam as guide-
lines have advocated. Secondly, there might be possible biases in
reviewing images. Lastly, the case numbers in Groups B–D were
relatively fewer than Group A. On the other hand, this is seemingly
the ﬁrst study addressing the outcome of patients, who underwent
enhanced follow-up strategy and other different presentation in
HCC surveillance. Our ﬁndings reﬂect observation from real-world
practice, and some parts of our study were not suitable for ran-
domized controlled trials. Future large-scale studies might help to
provide more suggestions to optimize surveillance program, and
are suggested.
In summary, the enhanced follow-up strategy by current guide-
lines was  appropriate for treatment to be deferred after a deﬁnite
diagnosis. Despite optimal surveillance interval and timely recall
policies, a few non-curative stage diagnoses seemed inevitable
under current standard of care.
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